A5100370477- Cancer Immunotherapy and Biomarkers
- Biosimilars and Bioanalytical Methods
- Lung Cancer Research Studies
- Statistical Methods in Clinical Trials
- CAR-T cell therapy research
- Pharmaceutical studies and practices
- Biomedical Ethics and Regulation
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Colorectal Cancer Surgical Treatments
- Microscopic Colitis
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Colorectal Cancer Treatments and Studies
- Immune Response and Inflammation
- Gastrointestinal Tumor Research and Treatment
- CRISPR and Genetic Engineering
- Pluripotent Stem Cells Research
- Ocular Oncology and Treatments
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
Nanfang Hospital
2023-2025
Southern Medical University
2023-2025
Health Canada
2012-2023
Huazhong University of Science and Technology
2022
Union Hospital
2022
Tianjin Medical University Cancer Institute and Hospital
2017
Liver kinase B1 (LKB1) mutation is prevalent and a driver of resistance to immune checkpoint blockade (ICB) therapy for lung adenocarcinoma. Here leveraging single cell RNA sequencing data, we demonstrate that trafficking adhesion process activated T cells are defected in genetically engineered Kras-driven mouse model with Lkb1 conditional knockout. LKB1 mutant cancer result marked suppression intercellular molecule-1 (ICAM1). Ectopic expression Icam1 Lkb1-deficient tumor increases homing...
Currently, the effect of inflammation on tumorigenesis and progression has been widely noted. As a member pattern recognition receptors, toll-like receptor 4 (TLR4) plays pivotal role in tumor immune microenvironment increasingly investigated. In present study, we evaluated TLR4 expression its association with programmed cell death ligand 1 (PD-L1) non-small lung cancer (NSCLC) tissues assessed predicting value postoperative outcome. A total 126 NSCLC patients receiving complete pulmonary...
On May 26, 2020, the FDA approved nivolumab with ipilimumab and two cycles of platinum-doublet chemotherapy as first-line treatment for patients metastatic or recurrent non-small cell lung cancer (NSCLC), no EGFR anaplastic lymphoma kinase (ALK) genomic tumor aberrations. The approval was based on results from Study CA2099LA (CheckMate 9LA), an open-label trial in which 719 NSCLC were randomized to receive (n = 361) four 358). Overall survival (OS) improved who received chemotherapy, a...
In May 2012, Health Canada and other participants held a National Summit on Subsequent Entry Biologics (SEBs). released guidance document in March 2010 describing policy positions data requirements for approval of SEBs. While health agencies regulatory jurisdictions are aligned many scientific principles related to biosimilar drugs, Canada's specific may not be widely understood by Canadian stakeholders. The provided an opportunity education dialog among physicians who prescribe biologics,...
On May 12, 2017, various issues and challenges associated with biologics were discussed during a session of the annual joint conference Canadian Society for Pharmaceutical Sciences Chapter Controlled Release at Hyatt Regency Hotel, Montréal, QC, Canada. An update on regulatory guidelines biosimilars was given, followed by viewpoints expressed regulatory, academic industry scientists. Topics discussion included: reference biologic drug, clinical considerations, immunogenicity, extrapolation...
Anti-PD-1/PD-L1 immunotherapy reactivates T-cell activity to boost the antitumor effect and may trigger autoimmune toxicity in various organ systems involving eyeball periocular structures at same time. The rarity of ocular immune-related adverse events should not prevent us from paying attention this issue because bad consequences visual impairment. This is first case report anti-PD-1 sintilimab-induced bilateral optic neuropathy a 76-year-old man with squamous non-small cell lung cancer...
e15650 Background: Traditional right hemicolectomy（TRH）is the standard operation for colon cancer. The resection includes intestines from terminal ileum to middle of transverse colon, as well ileocecum. ileocecum is considered have a “valve-like” function reduce intestinal reflux and incidence diarrhea, which also play an important role in enterohepatic circulation immunity. As cancers hepatic region proximal it possible preserve ensure oncological curative? Methods: We previously reported...